Voluntary nationwide recall: Brexafemme
Oct. 2023Pharmacy Updates
Scynexis, Inc. is recalling two lots of Brexafemme (ibrexafungerp tablets) due to potential cross-contamination with a nonantibacterial ß-lactam drug substance in the ibrexafungerp citrate used to manufacture the Brexafemme tablets. This drug is used as an antifungal for the treatment of vulvovaginal candidiasis (VVC) and the reduction of the incidence of recurrent vulvovaginal candidiasis (RVVC). Read the full text of the voluntary Brexafemme recall.
Recent Announcements
HPV Vaccination Resources
To help protect against cancers later in life, it is important to increase HPV vaccination rates in adolescents starting at age 9. According to the Centers for Disease Control and Prevention, HPV vaccination is routinely recommended at age 11 or 12, but the vaccine can be given starting at age 9.1 The Pennsylvania Cancer Coalition cites the following potential benefits of initiating the HPV vaccine series at age 9:2Mar. 2025Important Notices
Special notice: Important policy changes
Effective May 1, 2025, the following policies will be retired and replaced with prior authorization policies. For more information, please visit upmchp.us/policiesandprocedures.Mar. 2025Important Notices
CME Webinar: Essential Best Practices for Newborn Care: Ensuring Healthy Beginnings Through Comprehensive Care
Please join us for a live, CME-accredited webinar on Wednesday, May 7, from noon to 1 p.m. that will provide an overview of newborn care.Feb. 2025Education/Webinars